A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer

Clinical Cancer Research

Volumn 9, Issue 5, 2003, Pages 1639-1647

  Scott, Andrew M ^a   Wiseman, Greg ^b   Welt, Sydney ^a   Adjei, Alex ^b   Lee, Fook Thean ^a   Hopkins, Wendie ^a   Divgi, Chaitan R ^c   Hanson, Lorelei H ^b   Mitchell, Paul ^a   Gansen, Denise N ^b   Larson, Steven M ^c   Ingle, James N ^b   Hoffman, Eric W ^a   Tanswell, Paul ^d   Ritter, Gerd ^a   Cohen, Leonard S ^a   Bette, Peter ^d   Arvay, Lisa ^e   Amelsberg, Andree ^e   Vlock, Dan ^e   Rettig, Wolfgang J ^d   Old, Lloyd J ^a   more..

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b MAYO CLINIC   (United States)

^c MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^d BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^e BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; CELL PROTEIN; FIBROBLAST ACTIVATION PROTEIN; IODINE 131; SIBROTUZUMAB; UNCLASSIFIED DRUG;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BACKACHE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; COMPLEMENTARITY DETERMINING REGION; COUGHING; DOSE RESPONSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; DRUG UPTAKE; DYSPNEA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; FLUSHING; HUMAN; HYPERTENSION; HYPOXIA; IMMUNOGENICITY; ISOTOPE LABELING; LUNG NON SMALL CELL CANCER; MALE; MAXIMUM TOLERATED DOSE; METASTASIS; MULTICENTER STUDY; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RIGOR; SCINTILLATION CAMERA;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; CARCINOMA, NON-SMALL-CELL LUNG; COLORECTAL NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFUSIONS, INTRAVENOUS; IODINE RADIOISOTOPES; LUNG NEOPLASMS; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; RADIOIMMUNOTHERAPY; SERINE ENDOPEPTIDASES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 0037989982     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (23)

1. Dvorak, H. F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med., 315: 1650-1659, 1986.
2. Iozzo, R. V. Tumor stroma as a regulator of neoplastic behavior. Agonistic and antagonistic elements embedded in the same connective tissue. Lab. Investig., 73: 157-160, 1995.
3. Garin-Chesa, P., Old, L. J., and Rettig, W. J. Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. Proc. Natl. Acad. Sci. USA, 87: 7235-7239, 1990.
4. Van den Eynde, B. J., and Scott, A. M. Tumor antigens. In: P. J. Delves and I. M. Roitt (eds.), Encylopedia of Immunology, Ed. 2, Vol. 4, pp. 2424-2431. London: Academic Press, 1998.
5. Rettig, W. J., Garin-Chesa, P., Beresford, H. R., Oettgen, H. F., Melamed, M. R., and Old, L. J. Cell-surface glycoproteins of human sarcomas: differential expression in normal and malignant tissues and cultured cells. Proc. Natl. Acad. Sci. USA, 85: 3110-3114, 1988.
6. Levy, M. T., McCaughan, G. W., Abbott, C. A., Park, J. E., Cunningham, A. M., Muller, E., Rettig, W. J., and Gorrell, M. D. Fibroblast activation protein: a cell surface dipeptidyl peptidase and gelatinase expressed by stellate cells at the tissue remodelling interface in human cirrhosis. Hepatology, 29: 1768-1778, 1999.
7. Rettig, W. J., Su, S. L., Fortunato, S. R., Scanlan, M. J., Raj, B. K., Garin-Chesa, P., Healey, J. H., and Old, L. J. Fibroblast activation protein: purification, epitope mapping and induction by growth factors. Int. J. Cancer, 58: 385-392, 1994.
8. Rettig, W. J., Garin-Chesa, P., Healey, J. H., Su, S. L., Ozer, H. L., Schwab, M., Albino, A. P., and Old, L. J. Regulation and heteromeric structure of the fibroblast activation protein in normal and transformed cells of mesenchymal and neuroectodermal origin. Cancer Res., 53: 3327-3335, 1993.
9. Scanlan, M. J., Raj, B. K., Calvo, B., Garin-Chesa, P., Sanz-Moncasi, M. P., Healey, J. H., Old, L. J., and Rettig, W. J. Molecular cloning of fibroblast activation protein α, a member of the serine protease family selectively expressed in stromal fibroblasts of epithelial cancers. Proc. Natl. Acad. Sci. USA, 91: 5657-5661, 1994.
10. Mathew, S., Scanlan, M. J., Mohan Raj, B. K., Murty, V. V., Garin-Chesa, P., Old, L. J., Rettig, W. J., and Chaganti, R. S. The gene for fibroblast activation protein a (FAP), a putative cell surface-bound serine protease expressed in cancer stroma and wound healing, maps to chromosome band 2q23. Genomics, 25: 335-337, 1995.
11. Niedermeyer, J., Scanlan, M. J., Garin-Chesa, P., Daiber, C., Fiebig, H. H., Old, L. J., Rettig, W. J., and Schnapp, A. Mouse fibroblast activation protein: molecular cloning, alternative splicing and expression in the reactive stroma of epithelial cancers. Int. J. Cancer. 71: 383-389, 1997.
12. Park, J. E., Lenter, M. C., Zimmermann, R. N., Garin-Chesa, P., Old, L. J., and Rettig, W. J. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J. Biol. Chem., 274: 36505-12, 1999.
13. Cheng, J. D., Dunbrack, R. L., Jr., Valianou, M., Rogatko, A., Alpaugh, R. K., and Weiner, L. M. Promotion of tumor growth by murine fibroblast activation protein, a serine protease, in an animal model. Cancer Res., 62: 4767-4772, 2002.
14. Welt, S., Divgi, C. R., Scott, A. M., Garin-Chesa, P., Finn, R. D., Graham, M., Carswell, E. A., Cohen, A., Larson, S. M., Old. L. J., and et al. Antibody targeting in metastatic colon cancer: a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. J. Clin. Oncol., 12: 1193-203, 1994.
15. Tanswell, P., Garin-Chesa, P., Rettig, W. J., Welt, S., Divgi, C. R., Casper, E. S., Finn, R. D., Larson, S. M., Old, L. J., and Scott, A. M. Population pharmacokinetics of antifibroblast activation protein monoclonal antibody F19 in cancer patients. Br. J. Clin. Pharmacol., 51: 177-180, 2001.
16. Riechmann, L., Clark, M., Waldmann, H., and Winter, G. Reshaping human antibodies for therapy. Nature (Lond.), 332: 323-327, 1988.
17. Lee, F. T., Hall, C., Rigopoulos, A., Zweit, J., Pathmaraj, K., O'Keefe, G. J., Smyth, F. E., Welt, S., Old, L. J., and Scott, A. M. Immuno-PET of human colon xenograft-bearing BALB/c nude mice using 124I-CDR-grafted humanized A33 monoclonal antibody. J. Nucl. Med., 42: 764-769. 2001.
18. Heinzel, G., Woloszczak, W., and Thomann, P. TopFit: Pharmacokinetic and Pharmacodynamic Data Analysis System for the PC., Version 2.0 edition. Stuttgart: Gustav Fischer Verlag, 1993.
19. Ritter, G., Cohen, L. S., Williams, C., Jr., Richards, E. C., Old, L. J., and Welt, S. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33. Cancer Res., 61: 6851-6859, 2001.
20. LoBuglio, A. F., Wheeler, R. H., Trang, J., Haynes, A., Rogers, K., Harvey, E. B., Sun, L., Ghrayeb, J., and Khazaeli, M. B. Mouse/human chimeric monoclonal antibody in man: kinetics and immune response. Proc. Natl. Acad. Sci. USA, 86: 4220-4224, 1989.
21. Wiseman, L. R., and Faulds, D. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients. Drugs, 58: 1029-1042, 1999.
22. Baselga, J., Tripathy, D., Mendelsohn, J., Baughman, S., Benz, C. C., Dantis, L., Sklarin, N. T., Seidman, A. D., Hudis, C. A., Moore, J., Rosen, P. P., Twaddell, T., Henderson, I. C., and Norton, L. Phase 11 study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J. Clin. Oncol., 14: 737-744, 1996.
23. Everitt, D. E., Davis, C. B., Thompson, K., DiCicco, R., Ilson, B., Demuth, S. G., Herzyk, D. J., and Jorkasky, D. K. The pharmacokinetics, antigenicity, and fusion-inhibition activity of RsHz19, a humanized monoclonal antibody to respiratory syncytial virus, in healthy volunteers. J. Infect. Dis., 174: 463-469, 1996.